Larimar Shares Trade Higher On $95M Capital Raise, CTI-1601's Priority Medicines Tag In Europe

  • Larimar Therapeutics Inc LRMR has executed a securities purchase agreement to raise gross proceeds of approximately $95 million in a private placement.
  • The proceeds will be used to support the clinical development of CTI-1601, additional R&D, and working capital, and general corporate purposes.
  • Larimar will issue approximately 7 million shares at $13.43.
  • Each pre-funded warrant will have an exercise price of $0.01 per share and will be exercisable immediately.
  • The private placement is expected to close by May 25.
  • Today, CTI-1601 also received European Medicines Agency has granted Priority Medicines designation for Friedreich's ataxia.
  • Earlier this month, Phase 1 data showed that CTI-1601 led to dose-dependent increases in FXN levels from baseline versus the placebo controls.
  • The company also reported mortality in a 90-day and 180 day-non-human primate study at the highest dose levels.  
  • Price Action: LRMR shares are up 11.7% at $15 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFinancingFDAMoversTrading IdeasGeneralBriefsEuropean Medicines Agency (EMA)
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!